Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
about
Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 DiabetesComparative adherence to diabetes drugs: An analysis of electronic health records and claims data.Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA StudyRetrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus.Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE studyDurability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR).Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care.Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New DrugsComparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy usersComorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study.Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective AnalysisAdherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in JapanSelf-reported hypoglycaemia in patients with type 2 diabetes treated with insulin in the Hoorn Diabetes Care System Cohort, the Netherlands: a prospective cohort studyEffects of saxagliptin on early microvascular changes in patients with type 2 diabetes.Impact of Disease Management Programs on HbA1c Values in Type 2 Diabetes Patients in GermanyThe potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Hypoglycemia and risk of vascular events and mortality: a systematic review and meta-analysis.First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas.Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.Risk of Nonfatal Stroke in Type 2 Diabetes Mellitus Patients: A Retrospective Comparison Between Disease Management Programs and Standard Care.Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin.Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration.Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas.Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016).Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats.Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study
P2860
Q28073762-03787490-404A-4CEB-8084-F4890BEA2055Q31171523-CAD46119-54CE-4970-BD31-F81997CC4A4DQ33785141-D511D029-312B-41F9-BA7E-F4D632DE0BADQ34737169-096FF09A-546F-4FAA-9A76-96987B8A7866Q35128612-0C1C678F-FF23-4355-9710-8E3643D29F52Q35142675-8CAD47FD-481B-481E-99AD-311B74BDE49BQ35203980-034ACBF5-2EE8-400F-9B16-25BDC2D7B375Q36418794-40E3BD70-E250-48B5-B3A5-435405446E06Q36617758-696D2B9D-4F50-45A5-88F5-40532DFF2C6FQ36638899-B177D128-40FB-4583-955A-579E6F87C170Q37077942-E14C2734-9D03-485F-B3EF-9478D3D459F1Q37080656-9B56E994-DD14-492B-8BBD-CF430433798AQ37145172-02E5C9F1-274A-42EA-BD65-7110919875E4Q37208467-E96F87B2-C176-4E44-AF2A-B54D03C5B4EFQ37227402-167CC694-3C36-4CE1-A9E8-4AC5D0D51C95Q37271600-6F7B26EA-1060-4125-8272-C56E48232BDAQ37501142-A1F5E3C5-73FA-4EF0-BB8A-0AD763AB3F1CQ37732198-1ADDC821-73E7-4E64-877C-3A749708F16FQ38145277-DA0189DF-C496-4B96-ABB8-04F0FAA106DFQ38266290-2E57A01E-A9B5-4A2C-8B75-AAA3DF75DB81Q38335751-60616226-059A-4AC2-BD65-5A30CAB2E295Q38572028-A332A313-F408-4B27-BA86-99289AB64CC0Q38622203-2A59BC19-EEA7-49A8-A828-2DE741866B29Q38631429-107AD674-3DBA-40D8-AA4F-DD462FD3ABE5Q38789945-0A4B334B-06E0-480B-BC7A-B1668CB271B9Q38903839-1CCE674B-4C48-4B43-B15E-02F379C6570EQ39444863-4CCDA330-0B66-4037-BD5A-AE5F1EB3ECF5Q39484148-308F4CAD-563C-4270-8F12-E0153FB894B8Q40149577-64BA3482-569F-4B81-8D04-35567D34B7F5Q40681506-C8C5003E-07A8-4617-B633-F9C15F3C9039Q40756010-6D8968C8-134A-4122-9729-ADAE51E45D14Q41310853-A2BED026-C619-42DC-820F-BC3CD08B56D9Q43651118-07FB3051-A76B-4C3D-8048-12D832BC7AC7Q45905384-D01844AB-37C2-4837-A665-DDA6E2967487Q47665909-EC43FE15-E6E8-4AD5-9EE6-C42CC08BB9CEQ47690129-F9AC5297-8178-45D9-A623-532F3199CAD9Q50720671-09E14B68-952E-48C7-A9C0-44B7C3BF688CQ52954771-BF41B45C-E716-436A-8681-B0DD6BD3408DQ55192134-13DFCDE8-7DFB-44ED-A4E0-8992E3BEA483Q58767469-10BB76C6-417E-4B37-978B-32ECE5386B21
P2860
Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Treatment persistence, hypogly ...... rimary care database analysis.
@en
Treatment persistence, hypogly ...... rimary care database analysis.
@nl
type
label
Treatment persistence, hypogly ...... rimary care database analysis.
@en
Treatment persistence, hypogly ...... rimary care database analysis.
@nl
prefLabel
Treatment persistence, hypogly ...... rimary care database analysis.
@en
Treatment persistence, hypogly ...... rimary care database analysis.
@nl
P2093
P2860
P921
P1476
Treatment persistence, hypogly ...... rimary care database analysis.
@en
P2093
P2860
P356
10.1111/J.1463-1326.2012.01674.X
P577
2012-09-09T00:00:00Z